RespireRx Pharmaceuticals (RespireRx Pharmaceuticals) EBIT per Share : $-0.01 (TTM As of Sep. 2023)

View and export this data going back to 2009. Start your Free Trial

What is RespireRx Pharmaceuticals EBIT per Share?

RespireRx Pharmaceuticals's EBIT per Share for the three months ended in Sep. 2023 was $-0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.01.

During the past 3 years, the average EBIT per Share Growth Rate was 85.30% per year. During the past 5 years, the average EBIT per Share Growth Rate was 80.80% per year. During the past 10 years, the average EBIT per Share Growth Rate was 60.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for RespireRx Pharmaceuticals's EBIT per Share or its related term are showing as below:

RSPI' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -90.5 Med: 20 Max: 91
Current: 85.3

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of RespireRx Pharmaceuticals was 91.00% per year. The lowest was -90.50% per year. And the median was 20.00% per year.

RSPI's 3-Year EBIT Growth Rate is ranked better than
99.31% of 1305 companies
in the Biotechnology industry
Industry Median: 3.6 vs RSPI: 85.30

RespireRx Pharmaceuticals's EBIT for the three months ended in Sep. 2023 was $-0.32 Mil.

RespireRx Pharmaceuticals EBIT per Share Historical Data

The historical data trend for RespireRx Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RespireRx Pharmaceuticals EBIT per Share Chart

RespireRx Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT per Share

Get a 7-Day Free Trial

-7.33

-4.37

-0.02

-0.03

-0.01

RespireRx Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EBIT per Share	Get a 7-Day Free Trial															-	-	-	-	-

RespireRx Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

RespireRx Pharmaceuticals's EBIT per Share for the fiscal year that ended in Dec. 2022 is calculated as

	EBIT per Share		(A: Dec. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1.499	/	111.323
=	-0.01

RespireRx Pharmaceuticals's EBIT per Share for the quarter that ended in Sep. 2023 is calculated as

	EBIT per Share		(Q: Sep. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.322	/	267.733
=	-0.00

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01

RespireRx Pharmaceuticals (OTCPK:RSPI) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

RespireRx Pharmaceuticals EBIT per Share Related Terms

Thank you for viewing the detailed overview of RespireRx Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

RespireRx Pharmaceuticals (RespireRx Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RespireRx Pharmaceuticals Inc (OTCPK:RSPI) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

126 Valley Road, Suite C, Glen Rock, NJ, USA, 07452

Website

http://www.respirerx.com

RespireRx Pharmaceuticals Inc is engaged in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The pipeline products of the company are dronabinol which is developed for the treatment of OSA (Obstructive Sleep Apnea), a form of sleep apnea; CX1739 for the treatment of chronic central sleep apnea; CX717 and CX1942 is an injectable dosage for respiratory depression or vaso-occlusive passes associated with sickle cell disease. The company also focuses on developing another class of compounds called ampakines for the treatment of various respiratory disorders.

Executives

David Dickason	officer: SVP of Pre-Clinical Prod. Dev.	126 VALLEY ROAD, SUITE C, GLEN ROCK NJ 07452
Timothy L. Jones	director, officer: CEO and President	126 VALLEY ROAD, SUITE C, GLEN ROCK NJ 07452
Manuso James S J	director, officer: President & CEO	5130 ROUTE 212, WILLOW NY 12495
Katie Macfarlane	director	101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540
Purcell Richard David Jr.	officer: SVP - Research & Deleopment	65 FAIR HAVEN ROAD, FAIR HAVEN NJ 07704
James Sapirstein	director	1517 SAN JACINTO, HOUSTON TX 77002
Marc M Radin	officer: Controller	33 FRANKLIN PLACE, GLEN ROCK NJ 07452
Robert N Weingarten	director, officer: Vice President and CFO	5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367
Aurora Capital Llc	other: Member of a 10% owner group	354 WIDOW GAVITS ROAD, PO BOX 1167, BRIDGEHAMPTON, NY 11932-1167
Aurora Capital Corp	other: Member of 10% owner group
Jeff Eliot Margolis	director, officer: Vice President, Sec. & Treas., other: Member of 10% owner group	C/O AURORA CAPITAL LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
Steven Chizzik	other: Member of 10% owner group	C/O THE VERRAZANO GROUP, LLC, 2204 MORRIS AVENUE, SUITE 203A, UNION NJ 07083
Arnold Lippa	director, officer: Chairman, CEO and President, other: Member of 10% owner group	C/O AURORA CAPITAL, LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
T. Morgen Capital Llc	other: Member of 10% owner group	C/O AURORA CAPITAL LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
Kenneth M Cohen	other: Member of 10% owner group	12750 HIGH BLUFF DRIVE, SUITE 310, SAN DIEGO CA 92130